Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice.

Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC.

J Immunol. 2010 May 1;184(9):4605-9. doi: 10.4049/jimmunol.0903595.

2.

The role of IL-23/IL-17 axis in lupus nephritis.

Zhang Z, Kyttaris VC, Tsokos GC.

J Immunol. 2009 Sep 1;183(5):3160-9. doi: 10.4049/jimmunol.0900385.

3.
4.

Function of the Th17/interleukin-17A immune response in murine lupus nephritis.

Schmidt T, Paust HJ, Krebs CF, Turner JE, Kaffke A, Bennstein SB, Koyro T, Peters A, Velden J, Hünemörder S, Haag F, Steinmetz OM, Mittrücker HW, Stahl RA, Panzer U.

Arthritis Rheumatol. 2015 Feb;67(2):475-87. doi: 10.1002/art.38955.

5.

CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.

Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.

J Immunol. 2009 Oct 1;183(7):4693-704. doi: 10.4049/jimmunol.0802626.

6.

Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice.

Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R, Diaz M.

J Immunol. 2007 Jun 1;178(11):7422-31.

7.
8.

Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.

J Rheumatol. 2010 Jan;37(1):60-70. doi: 10.3899/jrheum.090194.

PMID:
19955044
9.

IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice.

Schwarting A, Tesch G, Kinoshita K, Maron R, Weiner HL, Kelley VR.

J Immunol. 1999 Dec 15;163(12):6884-91.

11.

Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.

Jiang C, Zhao ML, Scearce RM, Diaz M.

Arthritis Rheum. 2011 Apr;63(4):1086-96. doi: 10.1002/art.30230.

12.

Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.

Menke J, Bork T, Kutska B, Byrne KT, Blanfeld M, Relle M, Kelley VR, Schwarting A.

Kidney Int. 2011 Feb;79(4):452-63. doi: 10.1038/ki.2010.438.

13.

Perforin protects against autoimmunity in lupus-prone mice.

Peng SL, Moslehi J, Robert ME, Craft J.

J Immunol. 1998 Jan 15;160(2):652-60.

14.

Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.

Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ.

J Am Soc Nephrol. 2005 May;16(5):1326-38.

15.

Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.

Goury A, Meghraoui-Kheddar A, Belmokhtar K, Vuiblet V, Ortillon J, Jaisson S, Devy J, Le Naour R, Tabary T, Cohen JH, Schmidt AM, Rieu P, Touré F.

J Immunol. 2015 Apr 15;194(8):3612-22. doi: 10.4049/jimmunol.1402342.

16.

Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.

Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C.

J Immunol. 2012 Apr 15;188(8):3628-38. doi: 10.4049/jimmunol.1102859.

17.

Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.

Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ.

J Immunol. 2000 Sep 15;165(6):3436-43.

18.

Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.

Satoh M, Weintraub JP, Yoshida H, Shaheen VM, Richards HB, Shaw M, Reeves WH.

J Immunol. 2000 Jul 15;165(2):1036-43.

19.

Cytokine gene expression in the MRL/lpr model of lupus nephritis.

Lemay S, Mao C, Singh AK.

Kidney Int. 1996 Jul;50(1):85-93.

20.
Items per page

Supplemental Content

Support Center